Drugs / MHB039A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07126665 | Sep 2025 → Aug 2029 expected | cancer | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06345482 | Apr 2024 → Apr 2028 expected | neoplasm | Minghui Pharmaceutical (Hangzhou) Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07130383 | Sep 2025 → Aug 2029 expected | female breast carcinoma | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB039A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07126665 ↗ |
| Route | Intravenous | “MHB039A IV” NCT06345482 ↗ |